Experimental Drug Generates Immune Response Against Pancreatic Cancer in People at High Risk
Researchers at Johns Hopkins report that an experimental drug targeting one of the most common genetic drivers of pancreatic cancer was safe in humans, and generated durable immune responses aimed at preventing the cance
Researchers at Johns Hopkins report that an experimental drug targeting one of the most common genetic drivers of pancreatic cancer was safe in humans, and generated durable immune responses aimed at preventing the cance
